Quantcast

Latest carfilzomib Stories

2014-06-02 08:32:06

Results show adding LBH589 to bortezomib and dexamethasone significantly improved PFS by 37%, meeting Phase III study primary endpoint1 EAST HANOVER, N.J., June 2, 2014 /PRNewswire/ -- Novartis today presented results from a pivotal Phase III trial showing a 37% improvement in progression-free survival (PFS) when using the investigational compound LBH589 (panobinostat) in combination with bortezomib[*] and dexamethasone compared to treatment with the same regimen with placebo in patients with...

2014-04-29 08:35:40

Binimetinib Continues to Advance in Clinical Development BOULDER, Colo., April 29, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the third quarter of its fiscal year ending June 30, 2014. http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO Revenue for the third quarter of fiscal 2014 was $7.8 million, compared to $10.0 million for the same period last year. Revenue decreased due to reduction in recognition of license and milestone payments from our...

2014-04-07 08:29:25

CALGARY, April 7, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that research collaborators will make two poster presentations at the American Association for Cancer Research 2014 Annual Meeting. The Meeting is being held from April 6(th) to 9(th), 2014 in San Diego, CA. "The data presented by these collaborators is contributing to our evolving understanding of how REOLSYIN(®) works, what biomarkers may be predictive of improved...

2014-03-27 08:35:29

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/48gc9x/therapeutic_class ) has announced the addition of the "Therapeutic Class Overview: Treating Refractory Hematological Malignancies" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Targeting unmet needs in the treatment of cancer/ hematological malignancies through innovative drug development strategies have witnessed favorable...

2014-02-04 08:34:36

Robust Clinical Data on Filanesib Presented at ASH Supporting Announced Registration Program BOULDER, Colo., Feb. 4, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the second quarter of its fiscal year ending June 30, 2014. (Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) Revenue for the second quarter of fiscal 2014 was $14.1 million, compared to $18.4 million for the same period last year. The decrease was due to license...

2013-12-06 23:23:51

“Dual Inhibition Of Mcl-1 By The Combination Of Carfilzomib and TG02 In Multiple Myeloma” and “Leukemia Stem/Progenitor Cells From AML Patients Treated With The Multi-Kinase Inhibitor TG02 Demonstrate Increased Proliferation and Are Sensitized To Chemotherapeutic Agents” San Diego (PRWEB) December 06, 2013 Tragara Pharmaceuticals, Inc. today announced that two posters on TG02, the Company's unique oral multi-kinase inhibitor, will be presented at the American Society of...

2013-12-03 23:27:34

TG02 synergizes with carfilzomib in multiple myeloma models; data to be presented at ASH 2013 Annual Meeting. San Diego (PRWEB) December 03, 2013 Tragara Pharmaceuticals, Inc. today announced the initiation of a phase 1b clinical trial of TG02, in combination with the poteosome inhibitor carfilzomib (Kyprolis®), in patients with relapsed or refractory multiple myeloma. TG02 is a potent oral inhibitor of CDK9, which leads to the depletion of key survival proteins, such as Mcl-1,...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related